Boston Scientific (NYSE: BSX) reported earnings on July 26. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Boston Scientific missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped to a loss.

Gross margins increased, operating margins contracted, net margins dropped.

Revenue details
Boston Scientific tallied revenue of $1.83 billion. The 21 analysts polled by S&P Capital IQ predicted revenue of $1.89 billion on the same basis. GAAP reported sales were 7.4% lower than the prior-year quarter's $1.98 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.11. The 21 earnings estimates compiled by S&P Capital IQ forecast $0.10 per share. GAAP EPS were -$2.39 for Q2 compared to $0.10 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 65.8%, 270 basis points better than the prior-year quarter. Operating margin was 13.2%, 130 basis points worse than the prior-year quarter. Net margin was -186.2%, 19,360 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $1.83 billion. On the bottom line, the average EPS estimate is $0.11.

Next year's average estimate for revenue is $7.45 billion. The average EPS estimate is $0.42.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 752 members out of 936 rating the stock outperform, and 184 members rating it underperform. Among 182 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 159 give Boston Scientific a green thumbs-up, and 23 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.84.